Canadian experience of neoadjuvant chemotherapy on bladder recurrences in patients managed with trimodal therapy for muscle-invasive bladder cancer.

CONCLUSIONS: Receipt of NAC does not obviate the risk of bladder recurrence post-TMT. Patients with CIS should be monitored especially closely for local recurrence.
PMID: 32569566 [PubMed - as supplied by publisher]

Source: Canadian Urological Association Journal - June 15, 2020 Category: Urology & Nephrology Authors: Ajib K, Tjong MC, Tan GH, Nason G, Berjaoui MB, Erlich A, Maganti M, Sridhar S, Fleshner NE, Zlotta AR, Catton C, Berlin A, Chung P, Kulkarni GS Tags: Can Urol Assoc J Source Type: research